Eli Lilly offers $70 a share for Imclone

ImClone had announced that its mystery bidder would be revealed by Wednesday night at 11:59, and now the news is out. Pharma giant Eli Lilly has bid $6.1 billion, at $70 a share, according to a report in the Wall Street Journal. Insiders say Pfizer was also among BMS's competition, although the details of its bid have not be revealed. Eli Lilly has just before midnight tonight to make a decision.

Both Eli Lilly and Pfizer have been vocal about their desire to beef up their biotech pipelines. In a recent speech, Lilly chairman and CEO John Lechleiter (photo) reiterated the company's focus on biologics, saying that biotech drugs would be Lilly's preferred choice from now on. And just yesterday Pfizer announced an R&D revamp, which includes a greater focus on biologics.

- read this report for more

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.